Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inqovi and Thioguanine for Relapsed/Refractory AML
NCT06351306Phase 2Withdrawn
- Sponsor
- Columbia University
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of inqovi in acute myeloid leukemia (AML), sponsored by Columbia University. Primary endpoint: Composite Complete Remission Rate up to 3 years. Planned start Apr 2024; status: withdrawn.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06351306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351306.